Filing summary
Entity and period: The supplied filing is GlycoMimetics, Inc.’s Form 10-K for the fiscal year ended December 31, 2017, filed March 6, 2018. This does not match the request metadata naming Crescent BioPharma, Inc.; the filing identifies GlycoMimetics (Nasdaq: GLYC), a clinical-stage biotechnology company. The filing reports annual results, not a standalone fourth quarter, though unaudited quarterly figures are included.
Business context and pipeline
GlycoMimetics develops glycomimetic drug candidates. Its lead program, rivipansel for sickle-cell vaso-occlusive crisis, is licensed worldwide to Pfizer, which is responsible for further development and potential commercialization. The company retains rights to GMI-1271, an E-selectin inhibitor being developed with chemotherapy for AML and multiple myeloma, and GMI-1359, which targets E-selectin and CXCR4. Galectin-3 inhibitors remain preclinical.
Financial performance and liquidity
| Metric (US$ millions, except per-share data) | 2017 | 2016 | Change |
|---|---|---|---|
| Revenue | 0.0 | 0.019 | Down 0.019 |
| Research and development expense | 24.1 | 23.3 | Up 0.8 |
| General and administrative expense | 9.8 | 8.7 | Up 1.2 |
| Net loss | (33.3) | (31.8) | Loss widened 1.5 |
| Net loss per share | (1.13) | (1.50) | Improved |
| Operating cash used | 29.8 | 29.7 | About unchanged |
| Cash and cash equivalents at year-end | 123.9 | 40.0 | Up 83.9 |
Revenue was immaterial in 2016 and zero in 2017; the company reported no product sales. The 2017 net loss increased as expenses rose, despite higher interest income. R&D costs increased mainly from GMI-1271 clinical-supply manufacturing, partly offset by lower clinical-development spending after AML Phase 1/2 enrollment ended. G&A increased primarily with personnel and stock-based compensation. The filing does not present meaningful operating margins given the absence of material revenue.
Financing activities provided $113.9 million in 2017, principally from an $86.8 million public offering and at-the-market share sales. Shares outstanding rose from 23.25 million to 34.36 million during the year, a substantial source of dilution. Total liabilities were $8.9 million, primarily accounts payable, accruals and deferred rent; the filing reports no material debt. Current assets were $127.2 million against current liabilities of $8.2 million. Management estimated existing cash would fund operations and capital needs through at least the end of 2019, subject to assumptions and without relying on potential Pfizer milestones.
Material changes and notable items
- Cash increased sharply from 2016 following equity financings; operating cash use remained approximately $29.8 million.
- 2017 revenue was zero, compared with $20.1 million in 2015, when Pfizer milestone revenue was recognized. No Pfizer milestone or royalty payments were received in 2016 or 2017.
- The company recorded a $33.3 million annual net loss and an accumulated deficit of $152.3 million. It expects continued losses and does not forecast profitability.
- The 2017 tax-law change reduced the corporate tax rate, but the $15.2 million deferred-tax remeasurement was offset by the valuation allowance; deferred tax assets remained fully reserved.
- Operating-lease commitments totaled approximately $6.0 million through 2023. The company reported no off-balance-sheet arrangements and no material legal proceedings.
Outlook, clinical developments and risks
- GMI-1271 in AML: The company planned to begin a randomized Phase 3 trial in relapsed/refractory AML in the third quarter of 2018, targeting 380 adults at roughly 30–40 sites. Overall survival was to be the primary endpoint; preliminary results were expected by the end of 2020. These are forward-looking plans, not reported outcomes.
- AML Phase 1/2 results: Management reported remission and survival outcomes it considered favorable versus historical controls, including 43% remission and 9.4 months median overall survival in the relapsed/refractory group with available follow-up. These were interim, non-randomized results compared with historical controls and do not establish efficacy.
- Other programs: Initial topline data from the GMI-1271 multiple-myeloma trial were anticipated in Q1 2019. A HOVON study of GMI-1271 with decitabine in AML/MDS was expected to start in 2018. GMI-1359 remained in Phase 1 testing in healthy volunteers.
- Rivipansel: Pfizer’s Phase 3 trial was expected to complete enrollment in the second half of 2018, with preliminary results expected by year-end 2018. The company could receive development milestones of up to $115 million, regulatory milestones of up to $70 million, sales milestones of up to $135 million, and tiered royalties. Timing and achievement depend on Pfizer’s efforts and trial results; 10% of applicable future Pfizer payments is payable to the University of Basel under the research agreement.
- Funding and execution risks: The company expects to need additional capital and has no committed external funding source beyond potential Pfizer payments. Clinical failure or delay, slower enrollment, manufacturing and supply constraints, regulatory decisions, competition, reimbursement limits, intellectual-property challenges and dependence on third parties could materially affect prospects. Further equity financing could dilute shareholders.
Important facts for investors to verify
- Confirm the issuer: the filing is for GlycoMimetics, Inc., not Crescent BioPharma, Inc.
- Check subsequent disclosures for actual Phase 3 trial starts, enrollment, results and regulatory interactions for GMI-1271 and rivipansel.
- Review cash burn, financing activity and share-count changes after December 31, 2017; the runway estimate through 2019 was management’s estimate, not a guarantee.
- Assess the evidentiary limits of interim GMI-1271 findings based on historical controls, and distinguish them from randomized Phase 3 evidence.
- Verify Pfizer milestone and royalty conditions, the University of Basel payment obligation, and the company’s ability to obtain further funding.